Evidence map›Paper›PMID 31941234›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2019

[Progress and prospects of clinical cell therapy for liver cirrhosis and liver cancer].

K Liu, L F Wang, F S Wang, M Shi

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

K LiuPeking University 302 Clinical Medical School, Beijing 100039, China;Treatment and Research Center for Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
L F WangTreatment and Research Center for Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China;National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
F S WangPeking University 302 Clinical Medical School, Beijing 100039, China;Treatment and Research Center for Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China;National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
M ShiPeking University 302 Clinical Medical School, Beijing 100039, China;Treatment and Research Center for Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China;National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Peking University · CN

Funding

Innovation Groups of the National Natural Science Foundation of China 81721002National Key R&D Program of China 2017YFA0105703National Natural Science Foundation of China 81571567
6 · The paper itself

Abstract

The treatment options for liver cancer and liver cirrhosis are limited. Cell therapy (immune cells, stem cells) can significantly improve the therapeutic effect by actively regulating body's immunity. In addition, when choosing different methods of cell therapy, clinicians should also fully consider the adverse reactions associated with cell therapy. This article reviews the progress of cells therapy in clinical trials of liver cancer and liver cirrhosis, including therapeutic mechanism, advantages, disadvantages and limitations.

Indexed as

Cell- and Tissue-Based TherapyMesenchymal Stem Cell TransplantationHumansLiver CirrhosisLiver NeoplasmsMesenchymal Stem CellsCell therapyLiver cancerLiver cirrhosisMesenchymal stem cells

Identifiers

PMID31941234
PMCPMC12769352
OpenAlexW3007056074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.